SpringWorks Therapeutics Inc SWTX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 04/18/24 EDT
42.47quote price arrow down-1.64 (-3.72%)
Volume
774,905
52 week range
18.00 - 53.92
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close42.47
  • 52 Week High53.92
  • 52 Week High Date03/08/24
  • 52 Week Low18.00
  • 52 Week Low Date11/13/23

Key Stats

  • Market Cap3.145B
  • Shares Out74.06M
  • 10 Day Average Volume0.65M
  • Dividend-
  • Dividend Yield-
  • Beta0.86
  • YTD % Change16.36

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close42.47
  • 52 Week High53.92
  • 52 Week High Date03/08/24
  • 52 Week Low18.00
  • 52 Week Low Date11/13/23
  • Market Cap3.145B
  • Shares Out74.06M
  • 10 Day Average Volume0.65M
  • Dividend-
  • Dividend Yield-
  • Beta0.86
  • YTD % Change16.36

RATIOS/PROFITABILITY

  • EPS (TTM)-5.14
  • P/E (TTM)-8.26
  • Fwd P/E (NTM)-26.83
  • EBITDA (TTM)-341.346M
  • ROE (TTM)-54.90%
  • Revenue (TTM)5.447M
  • Gross Margin (TTM)92.25%
  • Net Margin (TTM)-5,968.50%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/01/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On SpringWorks Therapeutics Inc

 

Profile

MORE
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. OGSIVEO (nirogacestat) is the Company's Food and Drug Administration (FDA)-approved therapy. OGSIVEO (nirogacestat) is approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. The Company also has a diversified targeted therapy pipeline spanning solid tumors and hematological...
Daniel Lynch
Independent Chairman of the Board
Saqib Islam J.D.
Chief Executive Officer, Director
Badreddin Edris Ph.D.
Chief Operating Officer
Francis Perier Jr.
Chief Financial Officer
Herschel Weinstein J.D.
General Counsel, Secretary
Address
100 Washington Blvd
Stamford, CT
06902-9302
United States

Top Peers

SYMBOLLASTCHG%CHG
XENE
Xenon Pharmaceuticals Inc
40.31-1.32-3.17%
IDYA
IDEAYA Biosciences Inc
37.62-2.55-6.35%
IBRX
Immunitybio Inc
4.91-0.33-6.30%
IOVA
Iovance Biotherapeutics Inc
11.72-0.08-0.68%
CRNX
Crinetics Pharmaceuticals Inc
43.01-1.00-2.27%